They've already said that they have enough cash to take Brachysil to market. Only in March GR said that they decided not to support the Nasdaq listing with a capital raising because they did not need the cash and they didn't want to dilute everyone's shares. It would be received very badly to do a big raising now with the share price well down since the Nasdaq listing.
There's also the sale of the orthopaedics/tissue engineering part of the business. We don't know how that's going or how much cash it will bring, but a raising now would be interpreted as a lack of interest from buyers. And that's only weeks after PureTech, which is working on the sale, was issued a heap of options.
I see no capital raising on the horizon.
Pezz
PSD
psivida limited
